Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20144818 | 1.00 | IL1B (0.50) | IL1BNLRP3HCRTR1HCRTR2CHRM2 | |
| SCHEMBL20144750 | 0.83 | IL1B (0.55) | IL1BNLRP3HCRTR1 | |
| SCHEMBL20145221 | 0.83 | IL1B (0.55) | IL1BNLRP3HCRTR1 | |
| SCHEMBL20145042 | 0.81 | PDE3B (0.47) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL20145182 | 0.81 | IL1B (0.46) | IL1BNLRP3HCRTR1 | |
| SCHEMBL20145104 | 0.80 | KMT2A (0.46) | IL1BNLRP3HCRTR1HCRTR2 | |
| SCHEMBL20145101 | 0.76 | IL1B (0.46) | IL1BNLRP3HCRTR1CHRM2CHRM1 | |
| SCHEMBL20144981 | 0.76 | IL1B (0.46) | IL1BNLRP3HCRTR1CHRM2CHRM1 | |
| SCHEMBL25072354 | 0.75 | HMOX1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL20145199 | 0.75 | LIPE (0.55) | IL1BNLRP3HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |